OPKO Health, Inc. Deferred Revenue
OPKO Health, Inc. (OPK) had Deferred Revenue of $56.88 million as of 2017-12-31, per its 8-K filed 2019-01-29.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2019-01-29
- 2017-12-31: Deferred Revenue, Current $56.88M; Deferred Revenue, Current as first filed $46.19M.
- 2017-09-30: Deferred Revenue, Current $52.40M.
- 2017-06-30: Deferred Revenue, Current $74.95M.
- 2017-03-31: Deferred Revenue, Current $73.86M.
| Period end | Deferred Revenue, Current | Deferred Revenue, Current as first filed |
|---|---|---|
| 2017-12-31 | $56.88M 8-K · filed 2019-01-29 | $46.19M 10-K · filed 2018-03-01 |
| 2017-09-30 | $52.40M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $74.95M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $73.86M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $50.16M 8-K · filed 2019-01-29 | $73.43M 10-K · filed 2017-03-01 |
| 2016-09-30 | $72.56M 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $73.11M 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $74.38M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $70.25M 10-K · filed 2017-03-01 | |
| 2015-09-30 | $75.76M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $75.16M 10-Q · filed 2015-08-05 | |
| 2015-03-31 | $74.79M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $4.18M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $5.15M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $6.39M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $8.11M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $7.64M 10-K · filed 2015-02-27 | |
| 2013-09-30 | $7.04M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $3.90M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $1.59M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $1.52M 10-K · filed 2014-03-03 | |
| 2012-09-30 | $955.00K 10-Q · filed 2012-11-09 | |
| 2011-12-31 | $530.00K 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |